Cleveland Clinic Presents RVX-208 Data at American College of Cardiology (ACC) Conference in Washington DC March 31, 2014
"RVX-208 decreases Major Adverse Cardiac Events (MACE) in patients with systemic inflammation"
TSX Exchange Symbol: RVX
CALGARY, March 31, 2014 /PRNewswire/ - Resverlogix Corp. (TSX: RVX) today announced that ASSURE data will be presented at the ACC conference in Washington DC. The poster titled "Effects of an Apolipoprotein A-1 Inducer on Progression of Coronary Atherosclerosis and Cardiovascular Events in Patients with Elevated Inflammatory Markers" will be presented by Rishi Puri, Medical Director of Cleveland Clinic Atherosclerosis Imaging Core Laboratory. The poster authored by Rishi Puri, Yu Kataoka, Kathy Wolski, Allan Gordon, Jan Johansson, Norman Wong, Steven Nissen and Stephen Nicholls showed favorable effects of the apoA-I inducer RVX-208 on coronary disease progression and MACE. In patients with signs of systemic inflammation as indicated by a high sensitive C-reactive protein higher than 2mg/L, 6.9% of the RVX-208 treated patients had a Major Adverse Cardiac Event vs. 18.9% for the placebo treated patients (p<0.02). The prevention of cardiac events is the ultimate goal of treatment.
"We are very enthusiastic about the positive results from the ASSURE study on Major Adverse Cardiac Events in patients with signs of systemic inflammation. Seeing MACE reductions in phase 2 is an important signal and warrants confirmation in prospective studies," stated Donald McCaffrey, President and Chief Executive Officer of Resverlogix.
Resverlogix is also proud to announce completion of the treatment phase of its diabetes study "Phase 2 randomised, double-blind, placebo-controlled, cross-over study for the assessment of glucose metabolism changes with RVX-208 in individuals with pre-diabetes". Based on the hypothesis that ApoA-I has anti-diabetic actions, the objective of the trial is to show improved glucose balance by RVX-208 treatment, a drug known to induce ApoA-I production. This trial was coordinated by the principal investigators Professor Bronwyn Kingwell, Baker IDI Heart & Diabetes Institute and Dr. Stephen Duffy, The Alfred Hospital, Melbourne, Australia. Diabetes is a major cause of cardiovascular disease and beneficial effects of RVX-208 on Diabetes would provide additional treatment benefit in the treatment of Diabetes and its complications.
"The exploration of RVX-208's effects in Diabetes may be important for identifying additional indications beyond treatment of high risk atherosclerosis," stated Dr. Jan Johansson, Senior Vice President of Medical Affairs at Resverlogix. "BET inhibition and ApoA-I induction may be of importance in several therapeutic areas. We will continue to perform this important research which is still in its infancy," Dr. Johansson added.
RVX-208 is a first-in-class small molecule that inhibits BET bromodomains. RVX-208 functions by removing atherosclerotic plaque via reverse cholesterol transport (RCT), the natural process through which atherosclerotic plaque is transported out of the arteries and removed from the body by the liver. RVX-208 increases production of Apolipoprotein A-I (ApoA-I), the key building block of functional high-density lipoprotein (HDL) particles and the type required for RCT. These newly produced, functional HDL particles are flat and empty and can efficiently remove plaque and stabilize or reverse atherosclerotic disease. Analysis of recent clinical trials data showed that RVX-208 significantly reduces coronary atherosclerosis and major adverse cardiac events in patients with CVD who have a low level of HDL and elevated CRP, a population with unmet medical need. ApoA-I may also exert beneficial effects in Alzheimer's disease and Diabetes Mellitus. RVX-208 also has anti-inflammatory effects including effects on Interleukin-6 inhibition, vascular cell adhesion-1 and monocyte chemotactic protein-1, factors known to be involved in atherosclerosis and plaque stability.
Resverlogix Corp. (TSX:RVX) is a clinical stage cardiovascular company developing compounds involving a therapeutic increase in ApoA-I. Resverlogix's RVX-208 is a first-in-class small molecule for the treatment of diseases such as atherosclerosis and other chronic diseases such as Diabetes Mellitus and Alzheimer's disease. RVX-208 is the first BET bromodomain inhibitor in clinical trials. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog.
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to research and development activities and the potential role of RVX-208 in the treatment of atherosclerosis. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional assumptions and risk factors discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Donald J. McCaffrey
President and CEO
SVP Business & Corporate Development
SOURCE Resverlogix Corp.